Yeda Research and Develpment & Co. Ltd

Omrix Biopharmaceuticals Inc.

Miri Blank

Yehuda Shoenfeld

Israel Nur

Shmuel Cabilly

Ephraim Katchalski-Katzir

Specific peptides have been discovered that mimic an idiotype of an autoantibody. Such peptides may be formed into polymers. The peptides may be used in pharmaceutical compositions for the treatment of an autoimmune disease together with a pharmaceutically acceptable excipient.

Molecules mimicking an autoantibody idiotype and compositions containing same

A method for identifying molecules which mimic an idiotype of an autoimmune disease-associated auto-antibody (autoantibodies). The method comprises the following steps: (a) purifying autoantibodies from sera of one or more patients afflicted with the autoimmune disease; (b) binding the autoantibodies to a solid phase to form an affinity matrix; (c) contacting pooled plasma or B cells comprising immunoglobulins with the affinity matrix followed by removal of unbound plasma components; (d) eluting bound immunoglobulins, being anti-Idiotypic antibodies (anti-Id) to autoantibodies, from the matrix; (e) providing a molecular library comprising a plurality of molecule members; and (e) contacting the anti-Id with the molecular library and isolating those bound molecules which are bound by the anti-Id, the bound molecules being molecules which mimic an idiotype of autoantibodies. Also disclosed are such molecules.

Method for obtaining anti-idiotype antibodies

Synthetic peptides and derivatives thereof capable of inhibiting the biological activity of anti-beta-2-glycoprotein 1 (&#x3b2;2GPI) monoclonal antibodies (mAbs) in vitro, and of inhibiting induction of experimental anti-phospholipid syndrome (APS) in mice by anti-&#x3b2;2GPI mAbs, are provided for the diagnosis and treatment of anti-phospholipid syndrome in humans.

Synthetic peptides and kits for diagnosis of anti-phospholipid syndrome

Synthetic peptides and derivatives thereof capable of inhibiting the biological activity of anti-beta-2-glycoprotein 1 (&bgr;2GPI) monoclonal antibodies (mabs) in vitro, and of inhibiting induction of experimental anti-phospholipid syndrome (APS) in mice by anti-&bgr;2GPI mAbs, are provided for the diagnosis and treatment of anti-phospholipid syndrome in humans.

Growing community of inventors

Tel Aviv, Israel

Miri Blank